Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | TPMT | P51580 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrous Acid SCHEMBL28845232 | 0.93 | ALDH1A1 (0.50) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL11342868 | 0.91 | ALDH1A1 (0.47) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL668838 | 0.88 | KDM4E (0.69) | ALDH1A1KDM4ETDP1LMNATPMT | |
| SCHEMBL931870 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL5761347 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL13570729 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL31287794 | 0.84 | ALDH1A1 (0.76) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL567975 | 0.84 | ALDH1A1 (0.76) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL6964278 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4ETDP1LMNATAS1R3 | |
| SCHEMBL2658290 | 0.81 | KMT2A (0.43) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4562017-A1 | NOVEL ACC INHIBITORS | Pfizer Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120019059-A | Novel ACC inhibitors | 辉瑞公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-119431234-A | Benzyl amine formyl compound and preparation method and application thereof | 中国药科大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-1070060-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. Searle & Co. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ALDH1A1 3104/4885KDM4E 2200/4885TDP1 1030/4885 |
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885KDM4E 4460/4885TDP1 3930/4885 |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885KDM4E 4460/4885TDP1 3930/4885 |
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | ALDH1A1 414/4885KDM4E 3468/4885TDP1 3303/4885 |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885KDM4E 4460/4885TDP1 3930/4885 |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885KDM4E 4460/4885TDP1 3930/4885 |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885KDM4E 4460/4885TDP1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.